Sapio Sciences Introduces Sapio GMP LIMS Offering Unmatched Flexibility for Unique Manufacturing Processes

At the start of this year, Ed­i­tas Med­i­cine nar­rowed its pipeline and laid off 20% of its work­force, a move to save cash and fo­cus

Roivant re­port­ed a Phase 2 fail­ure on Tues­day for a pro­gram an­a­lysts ex­pect­ed would not suc­ceed. The com­pound in ques­tion, namilum­ab, was be­ing test­ed in